IUGNF News and Press, Imugene Ltd From 11/28/23

(NewsDirect) Imugene Ltd (ASX:IMU, OTC:IUGNF) CEO Leslie Chong and chief medical officer Dr Paul Woodard speak with Proactive following the news it’s been granted 'Fast Track' designation from the US Food and Drug Administration (FDA) for its MAST (metastatic advanced solid tumours) cl...

(NewsDirect) Imugene Ltd (ASX:IMU) CEO Leslie Chong speaks with Proactive soon after announcing the company has passed a major milestone for its Azer-cel therapy treatment with the dosing of the first patient for its Phase 1b Allogeneic CAR T Clinical Trial. It follows a Phase 1a trial that i...

(NewsDirect) Imugene Ltd (ASX:IMU) (OTCMKTS:IUGNF) CEO Leslie Chong talks Proactive through a clinical trial update of its Phase 1 MAST (Metastatic Advanced Solid Tumours) trial evaluating the safety and efficacy of novel cancer-killing virus CF33-hNIS (VAXINIA). Chong says the early positive...

(NewsDirect) Imugene Ltd (ASX:IMU, OTC:IUGNF) CEO Leslie Chong tells Proactive the company has marked a milestone with the start of its Phase 1 clinical trial for onCARlytics, a CD19 oncolytic virotherapy drug candidate. The trial, known as OASIS (Oncolytic Assessment and Safety in Solid Tumo...

(NewsDirect) Imugene Ltd (ASX:IMU) (OTCMKTS:IUGNF) MD Leslie Chong tells Proactive the company has received positive FDA feedback on an improved manufacturing process for azer-cel, an off the shelf CD19 CAR T cell therapy for blood cancers. She says the improved manufacturing process allows f...

(NewsDirect) Imugene Ltd (ASX:IMU, OTC:IUGNF) CEO Leslie Chong speaks with Proactive soon after the company announced it has cleared the first cohort of patients of the intratumoral (IT) arm of its VAXINIA metastatic advanced solid tumours (MAST) trial and is now recruiting for cohort 2 of th...

(NewsDirect) Imugene Ltd (ASX:IMU) managing director and CEO Leslie Chong speaks with Proactive soon after announcing the first patient has been dosed in the combination cohort of the IMPRINTER study - a clinical trial to evaluate the safety and efficacy of Imugene’s PD1- Vaxx in combi...

(NewsDirect) Imugene Ltd (ASX:IMU) managing director and CEO Leslie Chong takes Proactive’s Elisha Newell through an Investigational New Drug (IND) approval for the company’s first-in-class onCARlytics clinical trial. The IND greenlight, granted by the US Food and Dug Administra...

(NewsDirect) Imugene Ltd (ASX:IMU) CEO Leslie Chong tells Proactive that the company has dosed the first patients in cohort three of its intravenous (IV) and intratumoral (IT) monotherapy dose-escalation trial for novel cancer-killing virus VAXINIA (also known as CF33-hNIS). The City of Hope-...

(NewsDirect) Imugene Limited (ASX: IMU) CEO Leslie Chong tells Proactive the company’s Phase 1 MAST (metastatic advanced solid tumours) study evaluating the safety of novel cancer-killing virus CF33-hNIS (VAXINIA) has seen the first patients dosed in the intravenous and intratumoral (I...